Ansirh_ library—suggested reading on medical abortion
Reading list on medication abortion
Clark S, Ellertson C, Winikoff B. “Is medical abortion acceptable to all American women: the impact ofsociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion.” J Am MedWomens Assoc 2000;55(3 Suppl):177-82.
Joffe C. “Reactions to medical abortion among providers of surgical abortion: an early snapshot.” FamPlann Perspect 1999;31(1):35-8.
Winikoff B, Ellertson C, Elul B, Sivin I. “Acceptability and feasibility of early pregnancy termination bymifepristone-misoprostol. Results of a large multicenter trial in the United States. Mifepristone ClinicalTrials Group.” Arch Fam Med 1998;7(4):360-6.
Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Xiao B, Gu S, et al. “Safety, efficacy, and acceptability ofmedical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versussurgical abortion.” American Journal of Obstet Gynecol 1997;176(2):431-7.
Berer M. “Medical abortion: issues of choice and acceptability.” Reproductive Health Matters2005;13(26):25-34.
Clark WH, Gold M, Grossman D, Winikoff B. “Can mifepristone medical abortion be simplified? A reviewof the evidence and questions for future research.” Contraception 2007;75(4):245-50.
Ellertson, C., Elul, B., Winikoff, B. “Taking the medical out of medical abortion: Can women usemifepristone-misoprostol without medical supervision?” Reproductive Health Matters 1997;(9)149-161.
Elul B, Hajri S, Ngoc NN, Ellertson C, Slama CB, Pearlman E, et al. “Can women in less-developedcountries use a simplified medical abortion regimen?” Lancet 2001;357(9266):1402-5.
Gomperts RJ, Jelinska K, Davies S, Gemzell-Danielsson K, Kleiverda G. “Using telemedicine fortermination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe
services.” BJOG 2008;115(9):1171-5; discussion 1175-8.
Grossman D, Ellertson C, Grimes DA, Walker D. “Routine follow-up visits after first-trimester inducedabortion.” Obstet Gynecol 2004;103(4):738-45.
Harper C, Ellertson C, Winikoff B. “Could American women use mifepristone-misoprostol pills safely withless medical supervision?” Contraception 2002;65(2):133-42.
Provision by advanced practice clinicians
Berer M. “Provision of abortion by mid-level providers: international policy, practice and perspectives.”Bull World Health Organ 2009;87(1):58-63.
Hwang AC, Koyama A, Taylor D, Henderson JT, Miller S. “Advanced practice clinicians' interest inproviding medical abortion: results of a California survey.” Perspect Sex Reprod Health2005;37(2):92-7.
Yarnall J, Swica Y, Winikoff B. “Non-physician clinicians can safely provide first trimester medicalabortion.” Reprod Health Matters 2009;17(33):61-9.
Breitbart V. “Counseling for medical abortion.” Am J Obstet Gynecol 2000;183(2 Suppl):S26-33.
Integration of medication abortion into medical practices
Afable-Munsuz A, Gould H, Stewart F, Phillips KA, Van Bebber SL, Moore C. “Provider practice models forand costs of delivering medication abortion - evidence from 11 US abortion care settings.” Contraception2007;75(1):45-51.
Joffe C, Weitz TA. “Normalizing the exceptional: incorporating the "abortion pill" into mainstreammedicine.” Social Science & Medicine 2003;56(June):2353-2366.
Kawonga M, Blanchard K, Cooper D, Cullingworth L, Dickson K, Harrison T, et al. “Integrating medicalabortion into safe abortion services: experience from three pilot sites in South Africa.” J Fam PlannReprod Health Care 2008;34(3):159-64.
Leeman L, Asaria S, Espey E, Ogburn J, Gopman S, Barnett S. “Can mifepristone medication abortion besuccessfully integrated into medical practices that do not offer surgical abortion?” Contraception2007;76(2):96-100.
Shochet T, Trussell J. “Determinants of demand: method selection and provider preference among USwomen seeking abortion services.” Contraception 2008;77(6):397-404.
World Health Organization. Frequently Asked Clinical Questions about Medical Abortion. Conclusions ofan International Consensus Conference on Medical Abortion in Early First Trimester. Bellagio, Italy;2006.
Creinin MD. “Randomized comparison of efficacy, acceptability and cost of medical versus surgicalabortion.” Contraception 2000;62(3):117-24.
Lohr PA, Hayes JL, Gemzell-Danielsson K. “Surgical versus medical methods for second trimesterinduced abortion.” Cochrane Database Syst Rev 2008(1):CD006714.
Say L, Kulier R, Gulmezoglu M, Campana A. “Medical versus surgical methods for first trimestertermination of pregnancy.” Cochrane Database Syst Rev 2005(1):CD003037.
Wiegerinck MM, Jones HE, O'Connell K, Lichtenberg ES, Paul M, Westhoff CL. “Medical abortionpractices: a survey of National Abortion Federation members in the United States.” Contraception2008;78(6):486-91.
Creinin MD, Shore E, Balasubramanian S, Harwood B. “The true cost differential between mifepristoneand misoprostol and misoprostol-alone regimens for medical abortion.” Contraception2005;71(1):26-30.
Hu D, Grossman D, Levin C, Blanchard K, Goldie SJ. “Cost-effectiveness analysis of alternative first-trimester pregnancy termination strategies in Mexico City.” BJOG 2009;116(6):768-79.
Murthy A, Creinin MD. “Pharmacoeconomics of medical abortion: a review of cost in the United States,Europe and Asia.” Expert Opin Pharmacother 2003;4(4):503-13.
Van Bebber SL, Phillips KA, Weitz TA, Gould H, Stewart F. “Patient costs for medication abortion: results
from a study of five clinical practices.” Women's Health Issues 2006;16(1):4-13.
Hausknecht R. “Mifepristone and misoprostol for early medical abortion: 18 months experience in theUnited States.” Contraception 2003;67(6):463-5.
Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V. “Rates of serious infection after changes inregimens for medical abortion.” N Engl J Med 2009;361(2):145-51.
Kruse B, Poppema S, Creinin MD, Paul M. “Management of side effects and complications in medicalabortion.” Am J Obstet Gynecol 2000;183(2 Suppl):S65-75.
Shannon C, Brothers LP, Philip NM, Winikoff B. “Infection after medical abortion: a review of theliterature.” Contraception 2004;70(3):183-90.
Virk J, Zhang J, Olsen J. “Medical abortion and the risk of subsequent adverse pregnancy outcomes.” NEngl J Med 2007;357(7):648-53.
Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. “Factors affecting the outcome of early medicalabortion: a review of 4132 consecutive cases.” BJOG2002;109(11):1281-9.
Hedley A, Trussell J, Turner AN, Coyaji K, Ngoc NT, Winikoff B, et al. “Differences in efficacy, differencesin providers: results from a hazard analysis of medical abortion.” Contraception 2004;69(2):157-63.
Rev Méd Chile 2005; 133: 969-976 ARTÍCULO DE REVISIÓN Terapias emergentes en artritis reumatoide Juan C Aguillón G1,a, Andrea Cruzat C1,b, Juan Contreras-Levicoy1,b, Andrés Dotte G1,b, Bárbara Pesce R1,c, Octavio Aravena M1,c, Lorena Salazar A1,d, Diego Catalán M1,d, Paula Abello C1,e, Adam Aguirre D1,f, Carolina Llanos M1,2,g, Miguel Cuchacovich T2. Emergent therapies forrheum